HSP27 Multimerization Mediated by Phosphorylation-sensitive Intermolecular Interactions at the Amino Terminus*

Herman Lambert, Steve J. CharetteDagger , André F. Bernier, Alain Guimond, and Jacques Landry§

From the Centre de recherche en cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, Québec, Québec G1R 2J6, Canada

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Distinct biochemical activities have been reported for small and large molecular complexes of heat shock protein 27 (HSP27), respectively. Using glycerol gradient ultracentrifugation and chemical cross-linking, we show here that Chinese hamster HSP27 is expressed in cells as homotypic multimers ranging from dimers up to 700-kDa oligomers. Treatments with arsenite, which induces phosphorylation on Ser15 and Ser90, provoked a major change in the size distribution of the complexes that shifted from oligomers to dimers. Ser90 phosphorylation was sufficient and necessary for causing this change in structure. Dimer formation was severely inhibited by replacing Ser90 with Ala90 but not by replacing Ser15 with Ala15. Using the yeast two-hybrid system, two domains were identified that were responsible for HSP27 intermolecular interactions. One domain was insensitive to phosphorylation and corresponded to the C-terminal alpha -crystallin domain. The other domain was sensitive to serine 90 phosphorylation and was located in the N-terminal region of the protein. Fusion of this N-terminal domain to firefly luciferase conferred luciferase with the capacity to form multimers that dissociated into monomers upon phosphorylation. A deletion within this domain of residues Arg5-Tyr23, which contains a WDPF motif found in most proteins of the small heat shock protein family, yielded a protein that forms only phosphorylation-insensitive dimers. We propose that HSP27 forms stable dimers through the alpha -crystallin domain. These dimers further multimerize through intermolecular interactions mediated by the phosphorylation-sensitive N-terminal domain.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mammalian heat shock protein 27 (HSP27,1 also called HSP25) belongs to the phylogenically conserved small heat shock protein (smHSP) family that includes alpha A- and alpha B-crystallins. HSP27 is expressed constitutively in many tissues and cell lines, and its expression increases to high levels after various types of stress (1). By artificially manipulating the level of expression of HSP27, evidence has been accumulated suggesting that the protein modulates cell survival during stress (2-6), apoptosis mediated by the Fas/APO1 receptor (7), microfilament organization in response to growth factor or stress (3, 8-13), and growth rate or differentiation in some cell lines (14, 15). In endothelial cells where HSP27 is expressed constitutively at high levels, strong evidence has been presented suggesting that HSP27 is a mediator of vascular endothelial growth factor-induced microfilament reorganization and cell motility (16).

Phosphorylation was shown in many studies to modulate the activity of HSP27. The protein is phosphorylated on serine residues in a cascade of protein kinases involving MAPKAP kinase 2/3 and the stress-activated protein kinase SAPK2 (also called p38). The kinase cascade is activated, and HSP27 is phosphorylated in cells in response to chemical and physical stress such as heat shock, oxidative stress, or hyperosmotic stress and also in response to various physiological agonists involving serpentine, tyrosine kinase, or cytokine receptors (11, 17-23). HSP27 shares with other proteins of the smHSP family a common property to form large complexes in cells (1, 24-28). Sizes of 200-800 kDa have been reported for HSP27 (3, 29-31). The oligomeric size of the proteins is highly dynamic, and many of the treatments that induce HSP27 phosphorylation also induce changes in the size of the native protein (3, 31-34). It has been suggested that phosphorylation-induced changes in the ultrastructure may regulate the biochemical activities of HSP27.

Two biochemical activities have been described for HSP27 in vitro. A first activity is restricted to monomeric HSP27. In solution, purified monomers behave as F-actin cap-binding proteins and inhibit actin polymerization (35-37). Only unphosphorylated HSP27 could block actin polymerization, hence providing a mechanism to explain the in vivo observations that phosphorylation of HSP27 during stress or growth factor stimulation regulates actin polymerization and modulates filament stability or reorganization (3, 9, 13, 38). A second activity has been described for the oligomeric HSP27 complex. In vitro, high molecular weight recombinant HSP27 complexes can absorb heat-denatured proteins on their surface, preventing their aggregation and keeping them in a folding-competent state. The subsequent action of other chaperone proteins such as HSP70 leads to the renaturation of the unfolded proteins. (39, 40). Although not yet directly demonstrated, the mechanism proposed for this activity as well as studies performed with other smHSP suggested that the chaperone activity is limited to the oligomeric complexes (39-41). Both the chaperone and actin modulation activities could explain the protective action of HSP27 in vivo. However, specific chaperone functions regulating the activity or the stability of specific target proteins may also contribute to the homeostatic functions of HSP27. For example, oligomeric HSP27 binds to activated protein kinase B, a protein that lies in a survival pathway during stress (42-44). Monomers and dimers of HSP27 bind to granzyme A, a protease involved in granule-mediated cell lysis (45). Furthermore, a close relative of HSP27, MKBP, binds and modulates the activity of the myotonic dystrophy protein kinase (46). The role of HSP27 phosphorylation and multimeric state in modulating these interactions is unknown.

In the present study, we studied the relationships between the phosphorylation and the oligomerization properties of HSP27. Chinese hamster HSP27 (HaHSP27) is phosphorylated on two serine residues, Ser15 and Ser90. We show here that phosphorylation on Ser90 is sufficient and necessary to cause HSP27 to shift from a 700-kDa multimeric structure to dimers. Two homotypic binding domains were identified in HSP27. A first one, located within residues 95-186 of HaHSP27 (87-178 in HuHSP27), mediates dimerization and is insensitive to phosphorylation. A second one includes a small conserved stretch in the extreme amino terminus and is destabilized by phosphorylation of Ser90. We show that the N-terminal domain of HSP27 is sufficient to confer firefly luciferase with a phosphorylation-sensitive multimerization capacity.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasmids-- pSVHa27WT codes for wild type HaHSP27. It contains the HaHSP27 sequences from pH8 (8) inserted at the HindIII site of the vector pSVT7. Other HaHSP27 constructs were made from a derivative of pSVHa27WT, pSVHa27Mlu, in which a MluI restriction site was created by introducing a silent mutation in the third codon of HaHSP27. pSVHa27AA, pSVHa27EE, pSVHa27SA, pSVHa27AS, pSVHa27AE, and pSVHa27EA express phosphorylation site mutants of HaHSP27, the last two letters in the names corresponding to the replacement amino acid residues at position 15 and 90, respectively. Mutations were introduced in pSVHa27Mlu by polymerase chain reaction using specific synthetic oligonucleotide primers replacing the serine codon AGC by the alanine codon GCC or the glutamate codon GAA. pSVHa27Delta 5-23 was prepared by deleting the fragment MluI-KpnI in pSVHa27Mlu, yielding a protein lacking residues 5-23. pCMVHa5-109.Luc expresses a fusion protein made from residues 5-109 of HaHSP27 and the cytoplasmic firefly luciferase (L550V conversion in the peroxisomal localization signal; Ref. 47). The expression construct was made in two steps. First, a PvuII-SalI-MluI-BglII polylinker was added at the HindIII-XhoI site of the vector pCMVnlsLL/V (47), thereby removing the NLS site. This new vector named pCMVLuc yields the expression of a cytoplasmic luciferase with 12 amino acids added at the N terminus. Then, the fragment MluI-HincII from pSVHa27Mlu was inserted at the SalI-BglII restriction sites of pCMVLuc, resulting in a final expression construct coding for the fusion protein Met-Asn-Ser-Try(HaHSP27)5-109-Leu-Leu-Glu-Asn-(luciferase)4-549-Val.

Cell Culture, Transfection, and Lysis-- CCL39 and NIH3T3 cells were maintained at 37 °C in a 5% CO2 humidified atmosphere, in Dulbecco's modified Eagle's medium containing 2.2 g/liter NaHCO3 and 4.5 g/liter glucose and supplemented with 5% fetal calf serum or 10% calf serum, respectively. NIH3T3 cells were plated 24 h before transfection at a concentration of 5000-16,000 cells/cm2 in a 75-cm2 culture flask. Transfection by calcium phosphate precipitation was done as described before using 10 µg of plasmid/flask (2). 50 µM chloroquine was added for the first 5 h of transfection. The cells were used 48-72 h after transfection. When indicated, the cells were then treated for 2 h with 200 µM arsenite to induce phosphorylation of the expressed proteins. After treatment, the cells were lysed by brief sonication in 25 mM HEPES buffer, pH 7.4, containing 3.33% glycerol, 1 mM EDTA, 1 mM dithiothreitol, and 0.1 mM phenylmethylsulfonyl fluoride at 4 °C. The lysate was cleared by centrifugation at 17,000 × g for 5 min at 4 °C. The supernatant was used directly for glycerol gradient centrifugation or glutaraldehyde cross-linking.

Glycerol Gradient Centrifugation-- The cell lysates (0.5 ml) were loaded on top of a 12.6-ml linear gradient of glycerol (10-40%) made in 25 mM HEPES buffer, pH 7.4, containing 1 mM EDTA and 1 mM dithiothreitol. The tubes were centrifuged for 18 h at 30000 rpm in a SW40 rotor (Beckman) at 4 ° C. The gradient were fractionated in 44 fractions. Aliquots were diluted in Tris/glycine/SDS buffer (25 mM Tris, 192 mM glycine, 0.01% SDS) and dot-blotted on nitrocellulose membrane. HSP27 was revealed by immunoblotting using an antibody against the HaHSP27 C-terminal AGKSEQSGAK peptide (3). Antigen-antibody complexes were detected with a 125I-labeled goat anti-rabbit IgG. Detection and quantification were done using a Storm imaging system from Molecular Dynamics, Inc. (Sunnyvale, CA). Varying amounts of supernatant were also analyzed to confirm the linearity of the detection method. Luciferase was revealed from its activity. Aliquots (10 µl) of each fraction were diluted in 300 µl of 25 mM glycyl/glycine buffer, pH 7.8, containing 10 mM MgSO4, 2 mM ATP, and 1 mM dithiothreitol. Luciferase activity was measured in a Berthold Lumat 9501 luminometer for 30 s after the addition 100 µl of the substrate D-luciferin (50 µM final concentration). The gradient was calibrated from the positions of known protein complexes. The positions of the 20 S (700 kDa) and 15 S (340 kDa) proteasomes were determined by Western blot using an anti-HC8 antibody and confirmed by pore exclusion electrophoresis on native gel (48). The position of the 62-kDa firefly luciferase (produced in NIH3T3 cells transfected with pRSVLL/V (49)) was determined by measuring luciferase activity. The position of p38/stress-activated protein kinase 2 (38 kDa) was determined using an antibody against the C-terminal sequence PPLQEEMES of murine p38 (19).

Glutaraldehyde Cross-linking-- The cell lysates were mixed with one volume of 0-0.8% glutaraldehyde in water. After incubation for 30 min at 30 °C, the reaction was stopped by adding one volume of 1 M TRIS-HCl containing 10% SDS and 10 mM EDTA. Aliquots were analyzed by electrophoresis on a 3-10% SDS-polyacrylamide gel. Crossed-linked HSP27 species were detected by immunoblotting with antibody to HSP27.

Two-hybrid Screening and Analyses-- Two-hybrid assays were performed essentially as described in the CLONTECH Matchmaker Library user manual. Full-length Chinese hamster or human HSP27 cDNAs were cloned in the pBTM116 (TRP1) vector to produce the bait fusion protein LexA-HaHSP27 or LexA-HuHSP27 (50). The LexA-HaHSP27 construct was used to screen a HeLa cell cDNA library constructed at the EcoRI-XhoI site of the GAL4 activation domain plasmid pGADGH (LEU2) (CLONTECH). The LexA-HuHSP27 protein was used to screen a human kidney cDNA library constructed at the EcoRI site of the GAL4 activation domain plasmid pGAD10 (LEU2) (CLONTECH). Screening was performed by sequential transformation of bait and library vectors in the Saccharomyces cerevisiae reporter strain L40 (MATa trp1 leu2 his3 LYS2::lexA-HIS3 URA3::lexA-lacZ) (50, 51). Colonies that arose on Trp-/Leu-/His--selective plates were replica-plated, and one set was transferred to filter disks (Whatman Inc., Clifton, NJ) lysed by freezing, and tested for beta -galactosidase expression by incubation at 30 °C with 0.1 M NaPO4, 10 mM KCl, 1 mM MgSO4, 0.27% beta -mercaptoethanol, 0.33 mg/ml 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside, pH 7.0. LEU2 plasmids were isolated from the blue colonies and retested by co-transfection with Ras(V12) or lamin C fused to LexA to eliminate false positive clones (52). Inserts from the pGADGH or pGAD10 plasmids of the remaining true positive clones were sequenced to identify sequences of proteins belonging to members of the smHSP family (HSP27 and alpha A- and alpha B-crystallin).

Further two-hybrid assays were performed between pairs of GAL4 activation domain and LexA binding domain plasmids. GAL4 plasmids containing full-length HuHSP27, alpha A- and alpha B-crystallin cDNA, and N-terminal deletion mutants of HuHSP27 and alpha B-crystallin were as obtained from the screenings described above. LexA plasmids were constructed by recloning the insert of the GAL4 plasmids into pBMT116. Additional GAL4 and LexA C-terminal deletion mutants of HuHSP27 and alpha B-crystallin were obtained after digesting their corresponding full-length cDNA with HincII (yielding HuHSP27-(1-101) and alpha B-crystallin-(1-77)) and recloning in pBTM116 and pGADGH. All DNA constructs were confirmed by DNA sequencing. Interactions were determined by co-transfecting the pBTM116 and pGADGH or pGAD10 constructs in pairs in L40. Positive interactions were determined by the ability of the transformed yeast to grow on Trp-/Leu-/His- media and for their capacity to express beta -galactosidase (blue colonies) within 5 h.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Modulation of HSP27 Size Distribution by Phosphorylation-- CCL39 cell extracts were fractionated by ultracentrifugation on glycerol gradient, and each fraction was analyzed for the presence of HSP27 by immunoblotting. HSP27 sedimented as complexes of heterogeneous sizes distributed between the top of the gradient and fractions corresponding to a molecular mass of about 700 kDa (Fig. 1A). To better assess the nature of the HSP27 complex, increasing concentrations of glutaraldehyde was added to the cell extracts, and the cross-linked products were analyzed by SDS-polyacrylamide gel electrophoresis and HSP27 immunoblotting (Fig. 1B). With increasing concentrations of glutaraldehyde, HSP27 was cross-linked progressively in species showing a uniform ladder distribution of sizes with apparent molecular masses in multiples of 28 ± 1 kDa (determined by linear regression analysis of the position of the cross-linked products). These data indicate that no other proteins were associated stoichiometrically with HSP27 and, thus, that in situ the HSP27 complex is mainly a homopolymer. Some 700-kDa species, dimers, and monomers resisted cross-linking even at the highest concentration of glutaraldehyde. At this concentration, glutaraldehyde started to produce a general cross-linking of all proteins as revealed from the fainting of all protein bands on the Coomassie-stained gel (data not shown). These properties agreed with the sedimentation profile data and suggested that HSP27 was expressed in cells as large polymers of about 700 kDa in equilibrium with smaller species, mainly monomers and dimers.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 1.   Size distribution of endogenous HSP27 in CCL39 cells. CCL39 cells were treated () or not (black-square) with 200 µM arsenite for 2 h to induce phosphorylation of HSP27. A, the cell extracts were fractionated by centrifugation on glycerol gradient, and HSP27 in each fraction was detected by immunoblot. Molecular mass markers are indicated at the top: 20 S proteasome (700 kDa), 15 S proteasome (350 kDa), firefly luciferase (62 kDa), p38/SAPK2 (38 kDa). B, the cell extracts were incubated with increasing concentrations of glutaraldehyde (0, 0.001, 0.002, 0.005, 0.01, 0.02, 0.04, 0.06, 0.08, 0.1, 0.2, and 0.3%), the cross-linked proteins were separated on SDS-polyacrylamide gel electrophoresis, and HSP27 was detected by immunoblot. Molecular weight markers are shown on the left: thyroglobulin (cross-linked dimer, 670 kDa), thyroglobulin (335 kDa), myosin (200 kDa), beta -galactosidase (116 kDa), phosphorylase beta  (97 kDa), albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa).

HaHSP27 is phosphorylated on Ser15 and Ser90 by MAPKAP kinase 2, a serine kinase activated by the stress sensitive SAPK2/p38 kinase (20, 22). To analyze changes in the size distribution of HSP27 upon phosphorylation, CCL39 cells were exposed to arsenite for 2 h before extraction. Such treatment induced almost complete phosphorylation of HSP27 (data not shown) and a dramatic change in the size distribution profile of HSP27. After treatment, essentially all HSP27 was recovered in the first few fractions at the top of the glycerol gradient, between stress-activated protein kinase 2 (38 kDa) and firefly luciferase (62 kDa), and most of it could not be cross-linked in larger species than dimers (Fig. 1).

To confirm that phosphorylation was directly involved in modulating the supramolecular organization of HSP27, phosphorylation mutants of HaHSP27 were prepared by replacing Ser15 and Ser90 with alanine to mimic nonphosphorylatable serine residues (HaHSP27-AA) or with glutamate to mimic constitutively phosphorylated residues (HaHSP27-EE). These constructs were expressed in NIH 3T3 cells, and their size distribution was investigated as above. NIH 3T3 cells were chosen as recipient cells because they express negligible amounts of endogenous HSP27. As expected, HaHSP27-AA had a sedimentation profile and cross-linking pattern similar to those obtained with wild type HSP27 in untreated cells (Fig. 2) but did not shift to smaller sizes upon treatments that induce phosphorylation (not shown). In contrast, HaHSP27-EE was found almost exclusively as dimers and monomers in both control (Fig. 2) and treated cells (not shown). The relative importance of each site of phosphorylation was investigated by expressing single site mutants. HaHSP27, in which serine 15 was changed for alanine (HaHSP27-AS), behaved as the wild type protein (Fig. 3, B versus A). It distributed mainly as large multimers in control cells. After stress, it was found essentially as dimers and monomers (Fig. 3B). The data indicated that phosphorylation of serine 90 was sufficient and that phosphorylation of serine 15 was not required to cause the ultrastructural changes in HaHSP27. In contrast, HaHSP27 in which serine 90 was converted to alanine (HaHSP27-SA) had a normal size distribution in control cells and did not produce dimers or monomers after phosphorylation (Fig. 3C). This indicated that phosphorylation of serine 15 was not sufficient and that phosphorylation of serine 90 was necessary for the production of small molecular weight species. The results were confirmed by analyzing HaHSP27-EA and HaHSP27-AE double mutants. As expected, HaHSP27-EA was found mostly in large oligomeric complexes, whereas HaHSP27-AE was mostly found at the top of the gradient (Fig. 3D). We reproducibly observed that phosphorylated HaHSP27-SA and HaHSP27-EA yielded a peak slightly smaller than control HSP27. There is therefore a possibility that phosphorylation of serine 15 might affect the stability of the very high molecular weight species, causing a size shift in the 500-800-kDa range.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 2.   Size distribution of HaHSP27-AA and HaHSP27-EE mutants. NIH 3T3 cells were transfected with pSVHa27AA (black-square) or pSVHa27EE (). Cell extracts were fractionated by centrifugation on glycerol gradient (A) or were incubated (B) with increasing concentrations of glutaraldehyde (0, 0.001, 0.003, 0.01, 0,02, 0.05, and 0.1%), and the cross-linked proteins were separated by SDS-polyacrylamide gel electrophoresis. HSP27 was revealed by Western blot. Molecular mass markers are as described in the legend to Fig. 1.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   Size distribution of individual phosphorylation site mutants of HSP27. NIH 3T3 cells were transfected with pSVHa27WT (A), pSVHa27AS (B), pSVHa27SA (C), pSVHa27EA (black-square in D) or pSVHa27AE ( in D) and treated () or not (black-square, ) with 200 µM arsenite for 2 h. Cell extracts were fractionated by centrifugation on glycerol gradient, and HSP27 concentration was determined in each fraction by Western blot.

Domains Responsible for HSP27-HSP27 Interactions-- Information on the nature of the intermolecular binding domains of HSP27 was obtained in a two-hybrid screen made using full-length HaHSP27 or HuHSP27 fused to the LexA DNA-binding domain as bait. The plasmid libraries of fusions between the activation domain of Gal4 and cDNA from either HeLa cells or human kidney were screened in a yeast reporter system. In the HeLa cell library, 111 out of 193 clones that were confirmed as real HSP27 interacting proteins were full-length or N-terminal deletants of HuHSP27. The others corresponded to unidentified gene products distinct from HSP27. In the kidney library, 55 out of 92 real interacting partners were identified as full or partial length clones of HuHSP27. All the others were derived from the homologous alpha -crystallin proteins (29 alpha B-crystallin and 8 alpha A-crystallin), confirming previous studies indicating that HSP27 can form heterologous complexes with alpha -crystallins (53). In the HeLa cell library, all HuHSP27 variants were deleted at the N terminus, and the shortest clone started at residue 87; in the kidney library, all N-terminal deletants started before residue 87, and the most severe C-terminal deletant ended at residue 178. All alpha A-crystallin clones were full-length; the shortest alpha B-crystallin clone was an N-terminal deletant starting at residue 74 (corresponding to residue 102 in HaHSP27 and 94 in HuHSP27). A C-terminal alpha B-crystallin deletant ended at 162 (192 in HaHSP27; 184 in HuHSP27). This defined tentatively the HuHSP27 peptide containing residues 94-178 (corresponding to HaHSP27 residues 102-186) as a domain sufficient for HSP27-HSP27 interactions. Accordingly, we found that a C-terminal HuHSP27 peptide containing residues 87-205 gave a positive signal in the two-hybrid system when co-expressed with either full-length HuHSP27 or alpha A- or alpha B-crystallin. The HuHSP27 C-terminal peptide also interacted with itself and with a C-terminal peptide of alpha B-crystallin-(74-175) but not with the N-terminal residues 1-101 of HuHSP27 or 1-77 of alpha B-crystallin (Table I). This suggested the involvement of a C-terminal-C-terminal interaction in smHSP oligomerization.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Interacting domains in HSP27
Full length, N-terminal, and C-terminal human HSP27, alpha A-crystallin, and alpha B-crystallin were tested for interaction in the yeast two-hybrid system. Positive (+) interactions were determined as described under "Experimental Procedures."

To form multimeric structures, the C-terminal region of HSP27 must contain either a multivalent binding domain or two distinct monovalent binding domains. Another possibility is that a binding domain also exists in the N-terminal domain. This possibility was directly tested in the two-hybrid system. As shown in Table I, a peptide containing the first 101 residues of HuHSP27 did interact with full-length HuHSP27. However, no interaction was detected when the peptide was co-expressed with the C-terminal end. Similarly, an N-terminal peptide of alpha B-crystallin did interact with full-length HuHSP27 and with alpha A- and alpha B-crystallin but did not interact with the C-terminal peptide of either HuHSP27 or alpha B-crystallin. The results suggested that the N-terminal domain of smHSP also contains an intermolecular binding domain, probably mediating N-terminal-N-terminal interactions. It was not possible to test directly this interaction, since the fusion protein made of the N-terminal end of HuHSP27 or alpha B-crystallin and the transactivation domain yielded by itself a false positive signal.

All of these data are consistent with a model in which HSP27 would possess two homotypic interacting domains located in the N-terminal and C-terminal region, respectively. A prediction of this model is that deletion of either domain should produce a protein that forms smaller multimers. Although the N-terminal domain of smHSP is poorly conserved, a short conserved WDPF motif (see Fig. 6) is observed at the extreme N terminus of most smHSP (26). A plasmid containing coding sequences of HaHSP27 in which codons corresponding to residues Arg5-Tyr23 were deleted (Delta 5-23HSP27) was expressed in NIH-3T3 cells and analyzed by chemical cross-linking and ultracentrifugation. Delta 5-23HSP27 sedimented as a discrete peak at the top of the gradient and could not be significantly cross-linked in species larger than dimers (Fig. 4). Phosphorylation had little influence on the sedimentation profile or the cross-linking properties of the protein, suggesting that the dimers formed though C-terminal interactions are insensitive to serine 90 phosphorylation.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 4.   Size distribution of an Arg5-Tyr23 deletion mutant of HSP27. NIH 3T3 cells were transfected with pSVHa27Delta 5-23 and treated () or not (black-square) with 200 µM arsenite for 2 h. The cell extracts were fractionated by glycerol gradient centrifugation (A) or incubated with varying concentrations of glutaraldehyde (0, 0.005, 0.01, 0.02, 0.04, 0.1, and 0.2%) and analyzed by immunoblot after SDS-polyacrylamide gel electrophoresis (B).

A number of small deletions in the C-terminal domain were produced and tested for expression in NIH-3T3 cells. The constructs produced Triton-insoluble proteins that could not be analyzed further, suggesting that a major structural domain responsible for the stability or solubility of the protein is contained in these sequences. A fusion protein was therefore engineered containing the N-terminal sequences 5-109 of HaHSP27 (NH) fused to luciferase (LUC). Luciferase is a monomeric protein of about 62 kDa. NH-LUC (theoretical molecular mass of 75 kDa) formed multimers of more than 350 kDa in NIH-3T3 cells. Upon treatment with arsenite, the luciferase activity was shifted to fractions corresponding to 75 kDa, consistent with a phosphorylation-induced dissociation of the multimers into monomers (Fig. 5). The results indicated that the N-terminal end contains the phosphorylation-sensitive binding domain of HSP27.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Size distribution of a N-terminal HSP27-luciferase fusion protein. NIH 3T3 cells transfected with pCMVLuc (black-triangle) and left untreated or with pCMVHa5-109.Luc and treated () or not (black-square) with 500 µM arsenite for 1 h. Cell extracts were fractionated by glycerol gradient centrifugation, and the position of the expressed proteins was revealed by measuring the luciferase activity in each fraction.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

On the basis of the primary structure of smHSP from different organisms including plant, yeast, bacteria and mammalian, the position of introns in their respective genes, and the localization of well conserved amino acid residues, it has been suggested that smHSP are composed of two distinct domains (see Refs. 25 and 26 and Fig. 6). The C-terminal domain, also called the alpha -crystallin domain, is well conserved between the various species and constitutes the signature for proteins of this family. In contrast, the N-terminal domain is very weakly conserved except near the N terminus, where a similar hydrophobic motif is often observed. The rest of the N-terminal domain is highly variable both in length and in composition and probably forms at its end a connecting peptide to the C-terminal domain. Most smHSP end with a C-terminal tail of varying length. Alignments of mammalian HSP27 with other smHSP easily identify the two major domains. The C-terminal domain of HuHSP27 extends from residue 88 to 183 (from 96 to 191 in HaHSP27). In rodent HSP27, it has been determined by two-dimensional NMR that the last 18 residues of the C terminus form a highly flexible tail. The last 10 residues form a flexible peptide in alpha A- and alpha B-crystallins (54, 55). Human and rodent HSP27 are almost identical except for the presence of a shorter connecting peptide between the N- and C-terminal domains in the human protein. Both rodent and human HSP27 contain a site of phosphorylation located at serine 15 in the conserved hydrophobic motif. HuHSP27 has two sites of phosphorylation in the connecting peptide (serines 78 and 82). In rodents, the residue corresponding to serine 78 is replaced by an asparagine residue.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 6.   Conserved domains in small heat shock protein family members. A, the sequences of a few selected members of the small heat shock protein family were aligned to illustrate the position of the WDPF motif and alpha -crystallin domain (26). B, conservation of the WDPF motif. The sequences used are from HaHSP27 (National Center for Biotechnology Information (NCBI) accession no. 109436), HuHSP27 (NCBI accession no. 32478), human alpha B-crystallin (NCBI accession no. 2144811), pea HSP18.1 (NCBI accession no. 123555), rice HSP16.9 (NCBI accession no. 169799), Stigmatella aurantiaca sp21 (NCBI accession no. 548963), Methanococcus jannaschii HSP16.5 (NCBI accession no. 2495337), and S. cerevisiae HSP26 (NCBI accession no. 123568).

This study indicated that HSP27 exists in cell mainly as oligomers, which, after cross-linking and denaturation, distribute on an SDS gel in a regular ladder-like pattern of species whose masses are multiples of 28 kDa. This suggests that the structure is homotypic, i.e. formed only of HSP27. The results do not exclude the possibility that HSP27 can interact with other proteins in the cells, but they suggest that such an association is not stoichiometric. The most abundant form of HSP27 oligomers as revealed by ultracentrifugation has a molecular mass of about 700 kDa, which corresponds also to the size of the major cross-linked species obtained at high concentrations of glutaraldehyde. Some dimeric and monomeric species, however, appeared to resist cross-linking, and species with molecular mass lower than 700 kDa distributed along the glycerol gradient, suggesting that the structure might be highly dynamic, small species being in equilibrium with bigger ones. Such a high dynamic property has also been described for the structure of alpha A-crystallin, in which exchange of subunits between different oligomers occurs at high rates (56). Our results showed that upon phosphorylation of serine 90 but not of serine 15, most HSP27 complexes reduced also to dimers. Phosphorylation of serine 90 may shift the equilibrium for the formation of HSP27 complexes toward smaller species, perhaps by destabilizing the association of the dimers into higher molecular weight structures. Since mostly dimers were seen after phosphorylation, one could conclude that the dimer is the building block of the HSP27 complex. This conclusion is in line with that of Dudich et al. (57), who showed that the temperature dependence of the excessive heat capacity of the denaturation of HSP27 corresponds to a protein with a molecular mass of 50 kDa, suggesting that the dimer structure is a minimum cooperative subunit of the protein. The conclusion is also in agreement with the crystallographic data recently obtained for a distantly related bacterial smHSP, MjHSP16.5 (58). The analysis revealed a 24-subunit hollow spherical complex made of three asymmetric units of eight subunits, in which the strongest contacts occur between dimers. Although many of the residues involved in subunit contact of MjHSP16.5 are not conserved in HSP27, many of the structural features such as the basic symmetry may be conserved. A 24-mer of HSP27 would yield a size of 648 kDa, in close agreement with our estimated size of about 700 kDa.

Our data suggest that HSP27 oligomerizes through the interaction of two distinct binding domains. Both domains appear to act as independent binding modules that are required for oligomerization up to high molecular weight complexes. Analyses in the two-hybrid interaction assay system localized one of the binding domains between residues 94 and 178 of HuHSP27 (corresponding to HaHSP27 residues 102-186). This region corresponds almost exactly to the alpha -crystallin domain. It starts 6 residues after the position corresponding to intron I in alpha -crystallins and ends 7 residues before the beginning of the C-terminal flexible tail found in HSP27 (55). Although there is little known about the structure of HSP27, in several studies a role for this conserved domain as the building block of the quaternary structure of other members of this family has been suggested. In particular, the sequence extending between Tyr109 and Leu120 in alpha A-crystallin (Tyr133-Leu144 in HuHSP27; Tyr141-Leu152 in HaHSP27) was suggested to be the region where major intermolecular interactions occur (59). This sequence, which is very well conserved in mammalian smHSP (7 of 11 of these residues are conserved between alpha A-crystallin and HSP27), forms a beta -strand conformation in close proximity to the equivalent strand from opposing molecules. It also corresponds to the region of most extensive subunit contact in the recently crystallized MjHSP16.5 (58). The resemblance in primary structure between HSP27 and MjHSP16.5 makes it likely that the alpha -crystallin domain of HSP27 has also multiple subunit-subunit interacting surfaces that could mediate the formation of high order molecular complexes. Our data obtained with the N-terminal deletant of HSP27 suggest that by itself the C-terminal domain can only form stable dimers when expressed in vivo. However, N-terminal deletants of HSP27 or alpha B-crystallin purified from bacteria formed large molecular species after in vitro renaturation (60). We conclude that in the normal cell environment, the higher molecular weight multimers formed through C-terminal interactions are not stable and require to be stabilized by the N-terminal domain.

Indeed, our results indicated that the N terminus is also essential for the formation of HSP27 oligomers. We showed that this region, corresponding to exon I in alpha -crystallin, behaves as an independent structural domain, conferring upon fusion to luciferase the capacity to multimerize in a phosphorylation-sensitive manner. A role for the N terminus in providing essential stabilizing forces to smHSP oligomers has been suggested before (61, 62). Recombinant alpha A-crystallin in which the complete N-terminal domain was deleted formed dimers or tetramers upon renaturation (60, 63). Similarly, deletions of the first 15 residues in Caenorhabditis elegans HSP16.2 reduced considerably the size of the oligomers and its chaperone activity (41). The structure of smHSP appears to contain a large central cavity in which the rather hydrophobic N terminus is buried, being semiprotected from the environment but still keeping access to solvent (41, 58, 64). From our results, it could be proposed that N-terminal-N-terminal domain interactions in this central cavity stabilize the supramolecular organization of the dimers formed by the alpha -crystallin domain in the same way as they result in the multimerization of luciferase. Phosphorylation of serine 90 somehow weakens these N-terminal interactions, resulting in the dissociation of HSP27 into dimers. Serine 90 is located in a highly variable region suggested to form a connecting peptide between the alpha -crystallin and the N-terminal domains (25). It is possible that phosphorylation of serine 90 somehow modifies the structure of this connecting arm, which, for example, by changing the orientation of the two domains relative to each other would prevent the N terminus from gaining access to the central cavity and therefore prevent interactions and destabilize the oligomer.

The only relatively well conserved region in the N-terminal domain of distantly related smHSP is located at the extreme N terminus (26, 65). In Fig. 6, we refer to this region as the WDPF domain. The archetype pattern is found in the myxobacterium smHSP SP21, which contains two WDPF motifs separated by 8 residues. Although important variations in sequence are observed between species, some acidic (D or E), proline, and aromatic residues (W or F) appear to have been conserved even in the most distantly related species. We have shown that deletion of residues 5-23 within the WDPF domain of HaHSP27 results in the formation of dimers that were insensitive to phosphorylation. Mutations of conserved phenylanaline residues in the WDPF domain of alpha B-crystallin also abolish its chaperone activity (66). These results suggest that this domain may be directly involved in the stabilization of the HSP27 oligomer.

The role of serine 15 phosphorylation remains to be determined. As compared with phosphorylation of serine 90 or to deletion of the WDPF domain, phosphorylation of serine 15 did not cause a major effect on the structure of HSP27. However, a subtle effect on the stability of the higher molecular weight oligomers was observed and cannot be excluded completely without more investigations. Another possibility is that serine 15 modulates the interaction of HSP27 with other proteins. As stated before, the WDPF domain has been suggested to play a role in the chaperone function of alpha -crystalline (66). It is possible that phosphorylation of serine 15 regulates the interaction of this domain with unfolded proteins, which in the case of alpha -crystallin would occur in the central cavity where the N terminus also appears to be located (67). A similar situation occurs in the GroEL-GroES chaperone, which changes the hydrophobic characteristics of its cavity during the binding and refolding process (68, 69). Alternatively, phosphorylation of serine 15 may regulate the interaction of HSP27 with other proteins such as protein kinase B, granzyme A, or F-actin (35-37, 42, 45). In the case of actin, both the phosphorylation and the oligomeric state of HSP27 has been shown to modulate the interaction. An intriguing possibility is that upon phosphorylation of serine 90 and dissociation of the oligomer, the N-terminal domain becomes exposed and thus available for interaction with F-actin. The described effects of phosphorylation on the activities of HSP27 at the level of actin filament polymerization (37) suggest the additional possibility that once the oligomer is broken up following phosphorylation of serine 90, phosphorylation of serine 15 modulates the association of HSP27 with actin.

    ACKNOWLEDGEMENTS

We thank Olivier Bensaude of the École Normale Supérieure de Paris for useful discussions and the gift of the luciferase pCMVnlsLL/V plasmid.

    FOOTNOTES

* This study was supported by Medical Research Council Grant MT-7088.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by studentships from the Cancer Research Society, Inc. and the FCAR/FRSQ Santé, Québec.

§ To whom correspondence should be addressed. Centre de recherche en cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, 11 côte du Palais, Québec, Québec G1R 2J6, Canada. Tel.: 418-691-5555; Fax: 418-691-5439; E-mail: jacques.landry{at}med.ulaval.ca.

    ABBREVIATIONS

The abbreviations used are: HSP27, mammalian heat shock protein 25/27; HaHSP27, Chinese hamster HSP27; HuHSP27, human HSP27; smHSP, small heat shock protein.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Arrigo, A. P., and Landry, J. (1994) in The Biology of Heat Shock Proteins and Molecular Chaperones (Morimoto, R. I., Tissières, A., and Georgopoulos, C., eds), pp. 335-373, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  2. Landry, J., Chrétien, P., Lambert, H., Hickey, E., and Weber, L. A. (1989) J. Cell Biol. 109, 7-15[Abstract]
  3. Lavoie, J. N., Lambert, H., Hickey, E., Weber, L. A., and Landry, J. (1995) Mol. Cell. Biol. 15, 505-516[Abstract]
  4. Knauf, U., Jakob, U., Engel, K., Buchner, J., and Gaestel, M. (1994) EMBO J. 13, 54-60[Abstract]
  5. Mehlen, P., Preville, X., Chareyron, P., Briolay, J., Klemenz, R., and Arrigo, A. P. (1995) J. Immunol. 154, 363-374[Abstract/Free Full Text]
  6. Garrido, C., Ottavi, P., Fromentin, A., Hammann, A., Arrigo, A. P., Chauffert, B., and Mehlen, P. (1997) Cancer Res. 57, 2661-2667[Abstract]
  7. Mehlen, P., Schulze-Osthoff, K., and Arrigo, A. P. (1996) J. Biol. Chem. 271, 16510-16514[Abstract/Free Full Text]
  8. Lavoie, J. N., Gingras-Breton, G., Tanguay, R. M., and Landry, J. (1993) J. Biol. Chem. 268, 3420-3429[Abstract/Free Full Text]
  9. Lavoie, J. N., Hickey, E., Weber, L. A., and Landry, J. (1993) J. Biol. Chem. 268, 24210-24214[Abstract/Free Full Text]
  10. Huot, J., Houle, F., Spitz, D. R., and Landry, J. (1996) Cancer Res. 56, 273-279[Abstract]
  11. Huot, J., Houle, F., Marceau, F., and Landry, J. (1997) Circ. Res. 80, 383-392[Abstract/Free Full Text]
  12. Schafer, C., Ross, S. E., Bragado, M. J., Groblewski, G. E., Ernst, S. A., and Williams, J. A. (1998) J. Biol. Chem. 273, 24173-24180[Abstract/Free Full Text]
  13. Piotrowicz, R. S., and Levin, E. G. (1997) J. Biol. Chem. 272, 25920-25927[Abstract/Free Full Text]
  14. Piotrowicz, R. S., Weber, L. A., Hickey, E., and Levin, E. G. (1995) FASEB J. 9, 1079-1084[Abstract/Free Full Text]
  15. Mehlen, P., Mehlen, A., Godet, J., and Arrigo, A. P. (1997) J. Biol. Chem. 272, 31657-31665[Abstract/Free Full Text]
  16. Rousseau, S., Houle, F., Landry, J., and Huot, J. (1997) Oncogene 15, 2169-2177[CrossRef][Medline] [Order article via Infotrieve]
  17. Landry, J., Lambert, H., Zhou, M., Lavoie, J. N., Hickey, E., Weber, L. A., and Anderson, C. W. (1992) J. Biol. Chem. 267, 794-803[Abstract/Free Full Text]
  18. Gaestel, M., Schroder, W., Benndorf, R., Lippmann, C., Buchner, K., Hucho, F., Erdmann, V. A., and Bielka, H. (1991) J. Biol. Chem. 266, 14721-14724[Abstract/Free Full Text]
  19. Guay, J., Lambert, H., Gingras-Breton, G., Lavoie, J. N., Huot, J., and Landry, J. (1997) J. Cell Sci. 110, 357-368[Abstract/Free Full Text]
  20. Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llamazares, A., Zamanillo, D., Hunt, T., and Nebreda, A. R. (1994) Cell 78, 1027-1037[Medline] [Order article via Infotrieve]
  21. Stokoe, D., Engel, K., Campbell, D. G., Cohen, P., and Gaestel, M. (1992) FEBS Lett. 313, 307-313[CrossRef][Medline] [Order article via Infotrieve]
  22. Huot, J., Lambert, H., Lavoie, J. N., Guimond, A., Houle, F., and Landry, J. (1995) Eur. J. Biochem. 227, 416-427[Abstract]
  23. Landry, J., and Huot, J. (1995) Biochem. Cell Biol. 73, 703-707[Medline] [Order article via Infotrieve]
  24. de Jong, W. W., Hendriks, W., Mulders, J. W., and Bloemendal, H. (1989) Trends Biochem. Sci. 14, 365-368[CrossRef][Medline] [Order article via Infotrieve]
  25. de Jong, W. W., Leunissen, J. A., Leenen, P. J., Zweers, A., and Versteeg, M. (1988) J. Biol. Chem. 263, 5141-5149[Abstract/Free Full Text]
  26. de Jong, W. W., Leunissen, J. A., and Voorter, C. E. (1993) Mol. Biol. Evol. 10, 103-126[Abstract]
  27. Hickey, E., Brandon, S. E., Sadis, S., Smale, G., and Weber, L. A. (1986) Gene (Amst.) 43, 147-154[CrossRef][Medline] [Order article via Infotrieve]
  28. van den Ijssel, P. R., Smulders, R. H., de Jong, W. W., and Bloemendal, H. (1996) Ophthalmic Res. 28 Suppl. 1, 39-43[Medline] [Order article via Infotrieve]
  29. Arrigo, A. P., Suhan, J. P., and Welch, W. J. (1988) Mol. Cell. Biol. 8, 5059-5071[Medline] [Order article via Infotrieve]
  30. Behlke, J., Lutsch, G., Gaestel, M., and Bielka, H. (1991) FEBS Lett. 288, 119-122[CrossRef][Medline] [Order article via Infotrieve]
  31. Kato, K., Hasegawa, K., Goto, S., and Inaguma, Y. (1994) J. Biol. Chem. 269, 11274-11278[Abstract/Free Full Text]
  32. Mehlen, P., Mehlen, A., Guillet, D., Preville, X., and Arrigo, A. P. (1995) J. Cell. Biochem. 58, 248-259[Medline] [Order article via Infotrieve]
  33. Mehlen, P., and Arrigo, A. P. (1994) Eur. J. Biochem. 221, 327-334[Abstract]
  34. Chaufour, S., Mehlen, P., and Arrigo, A. P. (1996) Cell Stress Chaperones 1, 225-235[Medline] [Order article via Infotrieve]
  35. Miron, T., Wilchek, M., and Geiger, B. (1988) Eur. J. Biochem. 178, 543-553[Abstract]
  36. Miron, T., Vancompernolle, K., Vandekerckhove, J., Wilchek, M., and Geiger, B. (1991) J. Cell Biol. 114, 255-261[Abstract]
  37. Benndorf, R., Hayess, K., Ryazantsev, S., Wieske, M., Behlke, J., and Lutsch, G. (1994) J. Biol. Chem. 269, 20780-20784[Abstract/Free Full Text]
  38. Zhu, Y., O'Neill, S., Saklatvala, J., Tassi, L., and Mendelsohn, M. E. (1994) Blood 84, 3715-3723[Abstract/Free Full Text]
  39. Jakob, U., Gaestel, M., Engel, K., and Buchner, J. (1993) J. Biol. Chem. 268, 1517-1520[Abstract/Free Full Text]
  40. Ehrnsperger, M., Graber, S., Gaestel, M., and Buchner, J. (1997) EMBO J. 16, 221-229[Abstract/Free Full Text]
  41. Leroux, M. R., Melki, R., Gordon, B., Batelier, G., and Candido, E. P. (1997) J. Biol. Chem. 272, 24646-24656[Abstract/Free Full Text]
  42. Konishi, H., Matsuzaki, H., Tanaka, M., Takemura, Y., Kuroda, S., Ono, Y., and Kikkawa, U. (1997) FEBS Lett. 410, 493-498[CrossRef][Medline] [Order article via Infotrieve]
  43. Downward, J. (1998) Curr. Opin. Cell Biol. 10, 262-267[CrossRef][Medline] [Order article via Infotrieve]
  44. Franke, T. F., Kaplan, D. R., and Cantley, L. C. (1997) Cell 88, 435-437[Medline] [Order article via Infotrieve]
  45. Beresford, P. J., Jaju, M., Friedman, R. S., Yoon, M. J., and Lieberman, J. (1998) J. Immunol. 161, 161-167[Abstract/Free Full Text]
  46. Suzuki, A., Sugiyama, Y., Hayashi, Y., Nyu-i, N., Yoshida, M., Nonaka, I., Ishiura, S., Arahata, K., and Ohno, S. (1998) J. Cell Biol. 140, 1113-1124[Abstract/Free Full Text]
  47. Michels, A. A., Nguyen, V. T., Konings, A. W., Kampinga, H. H., and Bensaude, O. (1995) Eur. J. Biochem. 234, 382-389[Abstract]
  48. Yang, Y., Fruh, K., Ahn, K., and Peterson, P. A. (1995) J. Biol. Chem. 270, 27687-27694[Abstract/Free Full Text]
  49. de Wet, J. R., Wood, K. V., DeLuca, M., Helinski, D. R., and Subramani, S. (1987) Mol. Cell. Biol. 7, 725-737[Medline] [Order article via Infotrieve]
  50. Bartel, P. L., Chien, C., Sternglanz, R., and Fields, S. (1993) in Cellular Interactions in Development: A Practival Approach (Hartley, D. A., ed), pp. 153-179, IRL Press, Oxford
  51. Hollenberg, S. M., Sternglanz, R., Cheng, P. F., and Weintraub, H. (1995) Mol. Cell. Biol. 15, 3813-3822[Abstract]
  52. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. (1993) Cell 74, 205-214[Medline] [Order article via Infotrieve]
  53. Zantema, A., Verlaan-De Vries, M., Maasdam, D., Bol, S., and van der Eb, A. (1992) J. Biol. Chem. 267, 12936-12941[Abstract/Free Full Text]
  54. Carver, J. A., Aquilina, J. A., Truscott, R. J., and Ralston, G. B. (1992) FEBS Lett. 311, 143-149[CrossRef][Medline] [Order article via Infotrieve]
  55. Carver, J. A., Esposito, G., Schwedersky, G., and Gaestel, M. (1995) FEBS Lett. 369, 305-310[CrossRef][Medline] [Order article via Infotrieve]
  56. Bova, M. P., Ding, L. L., Horwitz, J., and Fung, B. K. (1997) J. Biol. Chem. 272, 29511-29517[Abstract/Free Full Text]
  57. Dudich, I. V., Zav'yalov, V. P., Pfeil, W., Gaestel, M., Zav'yalova, G. A., Denesyuk, A. I., and Korpela, T. (1995) Biochim. Biophys. Acta 1253, 163-168[Medline] [Order article via Infotrieve]
  58. Kim, K. K., Kim, R., and Kim, S. H. (1998) Nature 394, 595-599[CrossRef][Medline] [Order article via Infotrieve]
  59. Berengian, A. R., Bova, M. P., and McHaourab, H. S. (1997) Biochemistry 36, 9951-9957[CrossRef][Medline] [Order article via Infotrieve]
  60. Merck, K. B., Horwitz, J., Kersten, M., Overkamp, P., Gaestel, M., Bloemendal, H., and de Jong, W. W. (1993) Mol. Biol. Rep. 18, 209-215[Medline] [Order article via Infotrieve]
  61. Farnsworth, P. N., Frauwirth, H., Groth-Vasselli, B., and Singh, K. (1998) Int. J. Biol. Macromol. 22, 175-185[CrossRef][Medline] [Order article via Infotrieve]
  62. Carver, J. A., Aquilina, J. A., and Truscott, R. J. (1994) Exp. Eye Res. 59, 231-234[CrossRef][Medline] [Order article via Infotrieve]
  63. Merck, K. B., De Haard-Hoekman, W. A., Oude Essink, B. B., Bloemendal, H., and De Jong, W. W. (1992) Biochim. Biophys. Acta 1130, 267-276[Medline] [Order article via Infotrieve]
  64. Haley, D. A., Horwitz, J., and Stewart, P. L. (1998) J. Mol. Biol. 277, 27-35[CrossRef][Medline] [Order article via Infotrieve]
  65. Ehrnsperger, M., and Gaestel, M. (1998) in Molecular Chaperones in the Life Cycle of Proteins: Structure, Function and Mode of Action (Fink, A. L., and Goto, Y., eds), pp. 533-575, Marcel Dekker, New York
  66. Plater, M. L., Goode, D., and Crabbe, M. J. (1996) J. Biol. Chem. 271, 28558-28566[Abstract/Free Full Text]
  67. Boyle, D., Gopalakrishnan, S., and Takemoto, L. (1993) Biochem. Biophys. Res. Commun. 192, 1147-1154[CrossRef][Medline] [Order article via Infotrieve]
  68. Harrison, C. J. (1997) Structure 5, 1261-1264[Medline] [Order article via Infotrieve]
  69. Horovitz, A. (1998) Curr. Opin. Struct. Biol. 8, 93-100[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.